Decision For McNeil In Children's Motrin Suit Notes Limits Of OTC Labeling
This article was originally published in The Tan Sheet
Executive Summary
A federal court ruling cautions that drugs should not be expected to have labels that "guarantee against every conceivable adverse consequence.
You may also be interested in...
J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation
Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.
J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation
Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.
Judge Returns Motrin Suit To Trial Court, Reject's J&J's Motion To Dismiss
A California state appeals court rejected Johnson & Johnson's motion to dismiss a claim alleging the firm was negligent for not providing specific warnings about Stevens-Johnson Syndrome on Motrin labels.